PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA

This study is testing a new type of immunotherapy called liso-cel (Breyanzi) as the first treatment for primary central nervous system lymphoma (PCNSL), a rare brain cancer. The trial is for 65 adults who cannot have a stem cell transplant. Liso-cel is made from the patient's own…

This early-phase study tests whether combining two drugs, epcoritamab and ibrutinib, is safe for people whose central nervous system lymphoma has come back or not responded to treatment. About 26 adults with this rare cancer will receive the drug combination. The main goal is to …

This phase 2 trial tests a combination of four drugs—pirtobrutinib, sintilimab, rituximab, and high-dose methotrexate—as a first treatment for adults with newly diagnosed primary central nervous system lymphoma (PCNSL). About 77 participants will choose either this experimental c…

This study tests a combination of five drugs (R-PMDT) in 33 people newly diagnosed with primary central nervous system lymphoma, a rare brain cancer. The goal is to see how many patients' tumors shrink or disappear after six cycles of treatment. Researchers will also track how lo…

This study tests whether adding the drug ibrutinib to standard chemotherapy can better control primary central nervous system lymphoma (PCNSL) in people who are not eligible for a stem cell transplant. About 30 adults aged 65 or older or with other health issues will receive the …

This phase 2 trial is testing whether a combination of two drugs, zanubrutinib and pemetrexed, can safely control or shrink brain lymphomas that have come back or not responded to treatment. About 15 participants will receive the drugs in cycles, followed by maintenance therapy w…

This study is testing a combination of three drugs—pembrolizumab, ibrutinib, and rituximab—in people whose primary central nervous system lymphoma has returned or not responded to treatment. The goal is to see if the combination can stop the cancer from growing for at least 6 mon…

This pilot study tests whether adding the immunotherapy drug pembrolizumab (Keytruda) to standard chemotherapy can safely treat newly diagnosed primary central nervous system lymphoma. The trial will enroll 15 adults and primarily look for serious side effects, while also checkin…

This early-phase trial is testing a new type of CAR T cell therapy called Azer-cel, which is made from healthy donor cells rather than the patient's own cells. It aims to treat adults with relapsed or refractory non-Hodgkin lymphoma, B-cell acute lymphoblastic leukemia, and relat…

This early-stage study is testing a new immune cell therapy called CT1190B CAR-T in 27 adults with B-cell non-Hodgkin lymphoma that has come back or not responded to treatment. The therapy involves modifying a patient's own immune cells to better recognize and attack cancer cells…

This early-phase trial tests a drug called glofitamab, given after a pre-treatment with obinutuzumab, in 20 adults with central nervous system lymphoma. The goal is to check safety and side effects. Glofitamab is a bispecific antibody that helps the immune system attack cancer ce…

This early-stage trial is testing a new drug called Q702 in people with various blood cancers and related disorders that have not responded to standard treatments. Q702 is designed to help the immune system attack cancer cells and help the bone marrow make healthy blood cells. Th…